Standard BioTools Files Final Proxy for Treeline Reverse Merger — 84% Dilution, 1-for-20 to 1-for-40 Reverse Split
LAB is trading near its 52-week low of $0.625 (10% above the low).
Summary
Standard BioTools filed the final proxy statement for its reverse merger with Treeline Biosciences, quantifying the Exchange Ratio range (11.1202–11.7157), the 84%/16% ownership split favoring Treeline stockholders, and the proposed 1-for-20 to 1-for-40 reverse stock split to maintain Nasdaq listing.
Key Events · M&A and Partnerships · LAB
-
Reverse Merger Finalized
The all-stock merger with Treeline Biosciences values Treeline at $2.5 billion and Standard BioTools at $460 million, with the Exchange Ratio estimated between 11.1202 and 11.7157 Standard BioTools shares per Treeline share.
-
Massive Dilution for Existing Holders
Post-merger, former Standard BioTools stockholders will own approximately 16% of the combined company on a fully diluted basis, while Treeline stockholders will own 84%. Total fully-diluted shares are projected at 2.84 billion pre-Reverse Stock Split.
-
Reverse Stock Split Proposed
A 1-for-20 to 1-for-40 reverse stock split is proposed to meet Nasdaq's $4.00 minimum bid price requirement for initial listing. The final ratio will be mutually agreed by Standard BioTools and Treeline.
-
Legacy Business Divestitures
The filing discloses the Microfluidics Divestiture agreement with ARCHIMED dated October 4, 2026, and the Element Mass Cytometry Divestiture to Element Biosystems for $5.5 million. Proceeds from these divestitures will flow to CVR holders.
Analysis · LAB · Life Sciences
Amendment No. 2 to the S-4 registration statement finalizes the terms of the all-stock reverse merger with Treeline Biosciences. The Exchange Ratio range is now quantified at 11.1202 to 11.7157 shares of Standard BioTools common stock for each Treeline share, based on a $2.5 billion Treeline valuation and a $460 million Standard BioTools valuation. Existing Standard BioTools stockholders will own approximately 16% of the combined company on a fully diluted basis, with Treeline stockholders owning 84% — a massive dilution event. The filing also discloses the Microfluidics Divestiture agreement with ARCHIMED dated October 4, 2026, and quantifies the maximum share issuances under the CVR Agreement (76 million shares) and the Post-Closing Equity Incentive Plan (200 million shares). The total fully-diluted share count is projected at 2.84 billion shares pre-Reverse Stock Split. A 1-for-20 to 1-for-40 reverse stock split is proposed to meet Nasdaq's $4.00 minimum bid price requirement for initial listing. The merger is expected to close in Q4 2026, subject to stockholder approval at the Special Meeting.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 44% of the 307 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.6M. The 52-week trading range was $0.63 to $1.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.